Call for better endocrinology training in transgender health

A widespread lack of training, from medical school to advanced training, is hampering the hormonal management of trans and gender diverse (TGD) individuals in Australia. According to a survey of endocrinologists and trainee members of the Endocrine Society of Australia, only...

A widespread lack of training, from medical school to advanced training, is hampering the hormonal management of trans and gender...

Diabetes care

Goodbye Lantus, Hello Optisulin: Sanofi to swap long-acting insulin brands

Clinicians have six months to transition their patients using Sanofi’s long-acting insulin glargine Lantus over to the company’s second brand Optisulin. The pharmaceutical company has announced the recent PBS listing of Optisulin and at the same time...

Clinicians have six months to transition their patients using Sanofi’s long-acting insulin glargine Lantus over to the company’s...

Diabetes care

No evidence of metformin carcinogen contamination: TGA

Concerns that metformin products may contain a carcinogenic N-nitroso impurity have yet to be confirmed and patients should be strongly advised not to stop taking the medication, the TGA says. Following a recent recall of ranitidine products due to contamination with...

Concerns that metformin products may contain a carcinogenic N-nitroso impurity have yet to be confirmed and patients should be strongly...

Hormones

Adult patients with GH deficiency now eligible for PBS subsidised somatropin

PBS criteria for Growth Hormone (GH) prescribing have been eased to allow adult patients with childhood onset growth hormone deficiency (CO-GHD) to be eligible for PBS-subsidised adult use somatropin. From 1 January 2020, adults patients with CO-GHD due to a congenital,...

PBS criteria for Growth Hormone (GH) prescribing have been eased to allow adult patients with childhood onset growth hormone deficiency...